GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » EV-to-FCF

Pharmagreen Biotech (Pharmagreen Biotech) EV-to-FCF : -7.48 (As of May. 12, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Pharmagreen Biotech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmagreen Biotech's Enterprise Value is $1.03 Mil. Pharmagreen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-0.14 Mil. Therefore, Pharmagreen Biotech's EV-to-FCF for today is -7.48.

The historical rank and industry rank for Pharmagreen Biotech's EV-to-FCF or its related term are showing as below:

PHBI' s EV-to-FCF Range Over the Past 10 Years
Min: -48.51   Med: 0   Max: 0
Current: -7.48

PHBI's EV-to-FCF is ranked worse than
100% of 511 companies
in the Drug Manufacturers industry
Industry Median: 23.55 vs PHBI: -7.48

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Pharmagreen Biotech's stock price is $0.00095. Pharmagreen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.000. Therefore, Pharmagreen Biotech's PE Ratio for today is N/A.


Pharmagreen Biotech EV-to-FCF Historical Data

The historical data trend for Pharmagreen Biotech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech EV-to-FCF Chart

Pharmagreen Biotech Annual Data
Trend Apr08 Apr09 Sep18 Sep19 Sep20 Sep21 Sep22
EV-to-FCF
Get a 7-Day Free Trial -60.73 -294.37 -13.68 -51.85 -11.02

Pharmagreen Biotech Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.82 -11.02 -5.84 -9.17 -8.47

Competitive Comparison of Pharmagreen Biotech's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmagreen Biotech's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's EV-to-FCF falls into.



Pharmagreen Biotech EV-to-FCF Calculation

Pharmagreen Biotech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.025/-0.137
=-7.48

Pharmagreen Biotech's current Enterprise Value is $1.03 Mil.
Pharmagreen Biotech's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmagreen Biotech  (OTCPK:PHBI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharmagreen Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.00095/0.000
=N/A

Pharmagreen Biotech's share price for today is $0.00095.
Pharmagreen Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharmagreen Biotech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
112 North Curry Street, Carson, NV, USA, 89703
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.

Pharmagreen Biotech (Pharmagreen Biotech) Headlines